The present invention provides a vaccine containing a complex of a peptide consisting of the amino acid sequence of SEQ ID NO: 1 and an epitope of a disease-causing biological protein such as DPP4, IL-17A, IgE, S100A9 or PCSK9, which vaccine uses a less antigenic carrier protein and is capable of inducing antibody production to serve as an effective vaccine.

Provided herein are combination methods and compositions for cancer therapies. The combinations modify multiple arms of the immune system, including an innate immunity modifier, an immune checkpoint inhibitor and a T-cell stimulator, to treat cancer.

The invention provides an isolated essentially mammalian positive-sense single stranded RNA virus classifiable as belonging to the Order: Nidovirales; Family: Coronaviridae; Subfamily: Coronavirinae; Genus: Betacoronavirus; and non-Lineage A, non-Lineage B or non-Lineage D, human betacoronavirus. The invention also provides a human virus having a receptor binding domain (RBD) capable of binding to a dipeptidyl peptidase 4. The invention also provides diagnostic means and methods, prophylactic means and methods and therapeutic means and methods to be employed in the diagnosis, prevention and/or treatment of disease, in particular of respiratory disease, in particular of mammals, more in particular in humans.

The present disclosure relates to a compound and method of using such compound, preferably in the form of a dietary supplement that, when administered, is capable of treating thyroid disease and various thyroid-related disorders, such as Hashimoto's thyroiditis. The unique combination of the composition is preferably administered orally via acid resistant or enteric-coated capsule, soft gel or tablet. The composition is preferably comprised of at least Catalase, Reduced Glutathione, Acetylated Glutathione, DPP-IV protease enzyme, Pepsin, Bromelain, Pancreatin, Vitamin D, and Selenium. The composition can further comprise a palliative agent, and can be provided in specific dosages or administered in forms besides those listed above.

The invention provides a method and composition for ameliorating or reducing the symptoms, signs, and markers and for the treatment of irritable bowel syndrome, inflammatory bowel disease or gastritis in a mammal in need thereof, said method comprising administering effective amounts of a pharmaceutically acceptable composition containing at least one probiotic microorganism strain comprising Pediococcus for a time sufficient to ameliorate, reduce or treat at least one symptom, sign, or marker of irritable bowel syndrome, inflammatory bowel disease or gastritis.

The invention relates to novel bispecific antigen binding molecules, comprising (a) at least one moiety capable of specific binding to a target cell antigen, (b) at least one moiety capable of specific binding to a costimulatory TNF receptor family member, and (c) a Fc domain composed of a first and a second subunit capable of stable association, and to methods of producing these molecules and to methods of using the same.

The invention relates to antibody or antibody fragments thereof that bind to OX40, methods of producing these antibodies and fragments, and to methods of using the same.

Disclosed is a formulation of the following enzymes: Alpha-galactosidase, Alpha amylase, Beta Glucanase, Lactase, BioCor DPP=IV (Proprietary blend) and Pectinase, which has been found to be effective in treating histamine intolerant people, and causing a significant improvement in a wide variety of pathologies and symptoms, including, but not limited to: inflammation, pruritus, urticaria, hypotension, tachycardia, fatigue, migraines, conjunctivitis, incontinence, nasal congestion, panic attacks, acid reflux, depression and angioedema.

The present invention relates to the use of extracorporeal cardiac Shockwave therapy in the treatment or prophylaxis of heart disease, in particular the invention provides a dipeptidyl peptidase-4 (DPP-4) inhibitor, or a pharmaceutical composition containing said inhibitor, for use in: (a) treating or preventing heart failure; or (b) treating cardiac ischaemic reperfusion injury, in a subject, wherein said subject has been administered extracorporeal cardiac Shockwave therapy and wherein said inhibitor is for administration prior to, simultaneously with, and/or after administration of said Shockwave therapy.

A pharmaceutical composition for Positron Emission Tomography (PET) and Boron Neutron Capture Therapy (BNCT) and the use for treating cancer thereof are provided, wherein the pharmaceutical composition comprises a compound having structure of formula I, wherein R1 is a specific peptide, one of R2, R3, and R4 is Fluorine-18 (.sup.18F) or Fluorine-19 (.sup.19F), one of the other two position is B(OH).sub.2, and the remaining position is hydrogen (H); a method for preparing a compound having structure of formula I is also provided in the present invention.